Compare PASG & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASG | NSRX |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | Israel |
| Employees | 27 | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 25.8M |
| IPO Year | 2020 | N/A |
| Metric | PASG | NSRX |
|---|---|---|
| Price | $5.90 | $3.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $14.00 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 109.2K | 83.8K |
| Earning Date | 05-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $1.98 |
| 52 Week High | $20.00 | $9.99 |
| Indicator | PASG | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 54.86 |
| Support Level | N/A | $2.04 |
| Resistance Level | $8.65 | $5.20 |
| Average True Range (ATR) | 1.33 | 0.38 |
| MACD | -0.46 | 0.25 |
| Stochastic Oscillator | 2.54 | 49.62 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.